Intervention
Monitored home-based walking with weekly coaching (LITE protocol)
Research Observatory
Evidence Update
Current evidence
In LITE, adults with peripheral artery disease followed a monitored, home-based walking programme with weekly coaching. Comfortable low-intensity walking did not significantly improve six-minute walking distance over an educational control and was less effective than the higher-intensity programme that elicited leg symptoms. This disease-specific trial, with incomplete follow-up and study-related serious events, is not advice to walk through ischemic pain without clinical guidance.
What changed
LITE low-intensity walking did not improve six-minute walk distance over control and performed worse than high-intensity walking.
How to read these findings
This was home-based walking with monitoring and weekly coaching, not supervised exercise sessions. Low intensity versus control and low versus high intensity are separate comparisons.
CI means confidence interval, an uncertainty range for an estimate. This trial used adjusted 97.5% intervals, not 95% intervals. Events per person are event rates, not the percentage of people with an event. Do not treat these findings as advice to exercise through ischemic pain without clinical guidance.
Accepted limitations and study details
Exact reviewed qualifications are retained below. These details do not add a new accepted claim.
Study interpretation and limitations
- Do not turn an active-control contrast into advice to exercise through pain; disease-specific trial, 82% follow-up, adjusted 97.5% CIs.
- Design: Three-arm randomized home-based walking trial with accelerometer monitoring and weekly telephone coaching; exercise sessions took place in an unsupervised setting.
- Safety: Serious events/person: low 0.64, high 0.65, control 0.46; one study-related event in each exercise arm.
- Interpretation: Low-versus-high differs from low-versus-control; 97.5% not 95% intervals.
Why it matters
These findings apply to the studied populations, regimens and outcomes; they do not establish generalized longevity benefit.
Next proof
Implementation and safety-qualified replication preserving the trial’s clinical screening, monitoring and coaching; no unqualified exercise-through-pain advice.